Furthermore, EGCG markedly decreased endoglin levels in human ECs treated with semaxanib, a potent and selective inhibitor of VEGFR, thus exerting its anti-angiogenic function through targeting proangiogenic endoglin/Smad family member 1 (Smad1) signaling, which means combination therapies including EGCG will be promising to address the resistance of tumor cells to anti-VEGF therapies (148). The gene discussed is SMAD1; the disease is neoplasm.